Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 149   

Articles published

NVS 104.00 -0.79 (-0.75%)
price chart
Novartis AG (ADR) (NVS) And Juno Therapeutics Inc (JUNO) Reach Mutual ...
Novartis AG (ADR) (NYSE:NVS) and Juno Therapeutics Inc (NASDAQ:JUNO) have reached a settlement to their long-running patent war.
Novartis AG (ADR) To Pay $12.3 Million To Juno In CAR-T Patent Settlement  Bidness ETC
Sanofi SA (ADR) (SNY) And Novartis AG Lead In US New Drug Approvals Since ...
According to a recent Bloomberg report, Sanofi SA (ADR) (NYSE:SNY) and Novartis AG (ADR) (NYSE:NVS) have launched the highest number of drugs in the US since 2009.
GlaxoSmithKline plc (ADR) And Novartis AG (ADR) Complete Three-Part Deal ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS) announced on Monday that the two companies have completed a series of complicated asset swaps worth $20 billion, in what appears to be a move to tidy up asset portfolios to ...
Asset Swaps Of Novartis AG (ADR) (NYSE:NVS) and GlaxoSmithKline plc (ADR ...  Stocks.org
GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge  FiercePharma
GlaxoSmithKline plc (ADR) To Close Asset Swap Deal With Novartis AG (ADR ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced on Wednesday that it anticipates closing the mega-billion dollar asset exchange with Novartis AG (ADR) (NYSE:NVS) in the week beginning March 2, 2015. However, the deal, which is expected to make ...
Novartis AG (NYSE:NVS) & GlaxoSmithKline PLC (NYSE:GSK) Receive a Green ...  WallStreet.org
Novartis AG (ADR) (NYSE:NVS)'s Farydak Gets Approval From FDA
Novartis AG (ADR) (NYSE:NVS)'s multiple myeloma treatment Farydak received FDA approval, despite an advisory panel's recommendation against approval.
BMJ Says Novartis AG (ADR) Hindered Trials That Pitted Lucentis Against ...
Novartis AG (ADR) (NYSE:NVS) has been accused of thwarting publicly-funded UK-based trials that attempted to test the safety and efficacy of Avastin, a cheaper potential alternative therapy, to Novartis' eye drug Lucentis for the treatment of wet age ...
Novartis AG (ADR), GlaxoSmithKline plc (ADR) Recieve Final Approval For Thee ...
According to the US Federal Trade Commission's (FTC) announcement yesterday, Novartis (NYSE:NVS) has received the US antitrust regulator's approval to acquire drugs from Glaxo's oncology portfolio, contingent upon certain specified conditions.
Novartis AG (ADR) (NYSE:NVS) Grows Strong In Opthal with Pazeo Approval
Novartis AG (ADR) (NYSE:NVS) Alcon's solution, Pazeo solution is an olopatadine hydrochloride solution. Ophthalmic solutions for the treatment of certain conditions, such as conjunctivitis caused by allergens require high efficacy levels.
Pharma's Record Setting First Quarter [Actavis plc, Allergan, Inc., Eli Lilly ...
Some major deals have contributed to that record-breaking total. In March, AbbVie Inc. (NYSE: ABBV) announced the purchase of Pharmacyclics Inc.(Nasdaq: PCYC) for $21 billion.
Novartis AG (ADR) Zarxio Becomes First Biosimilar Approved For Sale In US
Novartis AG (ADR) (NYSE:NVS) on Friday won the US Food and Drug Administration's (FDA) approval for its biosimilar drug Zarxio, a cheaper imitation version of Amgen, Inc.'s (NASDAQ:AMGN) Neupogen, making Zarxio the first ever biosimilar to be ...